NASDAQ:PSNL Personalis (PSNL) Stock Price, News & Analysis $5.84 -0.50 (-7.89%) (As of 10:51 AM ET) Add Compare Share Share Today's Range$5.71▼$6.4550-Day Range$1.17▼$6.3452-Week Range$0.89▼$7.20Volume919,396 shsAverage Volume691,417 shsMarket Capitalization$309.99 millionP/E RatioN/ADividend YieldN/APrice Target$6.81 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Personalis alerts: Email Address Personalis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside16.7% Upside$6.81 Price TargetShort InterestHealthy3.41% of Shares Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.56Based on 21 Articles This WeekInsider TradingSelling Shares$3,760 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.12) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.76 out of 5 starsMedical Sector340th out of 924 stocksMedical Laboratories Industry10th out of 18 stocks 2.5 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePersonalis has only been the subject of 3 research reports in the past 90 days.Read more about Personalis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.41% of the outstanding shares of Personalis have been sold short.Short Interest Ratio / Days to CoverPersonalis has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Personalis has recently increased by 19.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePersonalis has received a 60.70% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools" and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Personalis is -0.66. Previous Next 3.1 News and Social Media Coverage News SentimentPersonalis has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Personalis this week, compared to 2 articles on an average week.Search Interest25 people have searched for PSNL on MarketBeat in the last 30 days. This is an increase of 257% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,760.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Personalis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.12) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Personalis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradingTipsBuy these “two-bagger” stocksWe’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.Download your free report today! About Personalis Stock (NASDAQ:PSNL)Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Read More PSNL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PSNL Stock News HeadlinesAugust 21 at 4:46 PM | markets.businessinsider.comPersonalis (PSNL) Receives a Buy from BTIGAugust 20 at 5:02 AM | americanbankingnews.comPersonalis (NASDAQ:PSNL) PT Raised to $9.00August 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 19 at 7:11 PM | benzinga.comAssessing Personalis: Insights From 4 Financial AnalystsAugust 19 at 7:11 PM | markets.businessinsider.comLake Street Remains a Buy on Personalis (PSNL)August 19 at 7:11 PM | markets.businessinsider.comPersonalis (PSNL) Receives a Buy from TD CowenAugust 19 at 2:50 AM | americanbankingnews.comBTIG Research Boosts Personalis (NASDAQ:PSNL) Price Target to $7.00August 18, 2024 | americanbankingnews.comPersonalis (NASDAQ:PSNL) PT Raised to $7.25 at Needham & Company LLCAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 16, 2024 | marketwatch.comPersonalis Surges 19% on Expanded Tempus PartnershipAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Personalis Amidst Rapid Commercialization and Strong Tempus AI PartnershipAugust 16, 2024 | markets.businessinsider.comBuy Rating Upheld for Personalis Inc. with Increased Price Target Amid Strong Market Demand and Financial StabilityAugust 16, 2024 | finance.yahoo.comPersonalis and Tempus Announce Expanded CollaborationAugust 13, 2024 | marketwatch.comPersonalis Shares Rise 25% on 2Q Revenue Beat, GuidanceAugust 13, 2024 | markets.businessinsider.comBalanced Hold Rating for Personalis Amidst Growth Potential and Near-Term ChallengesAugust 13, 2024 | americanbankingnews.comPersonalis, Inc. (NASDAQ:PSNL) Expected to Post Q3 2024 Earnings of ($0.25) Per ShareAugust 9, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Personalis Amid Robust Revenue Growth and Optimistic MRD Test Market PenetrationAugust 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Personalis (PSNL)See More Headlines Receive PSNL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:PSNL CUSIPN/A CIK1527753 Webwww.personalis.com Phone(650) 752-1300FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$6.81 High Stock Price Target$9.00 Low Stock Price Target$4.00 Potential Upside/Downside+7.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,300,000.00 Net Margins-101.78% Pretax Margin-101.73% Return on Equity-56.87% Return on Assets-35.08% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.05 Sales & Book Value Annual Sales$80.03 million Price / Sales4.11 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book2.99Miscellaneous Outstanding Shares51,939,000Free Float49,810,000Market Cap$329.29 million OptionableOptionable Beta1.85 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Christopher M. Hall (Age 55)President, CEO & Director Comp: $963.75kMr. Aaron L. Tachibana (Age 63)CFO & COO Comp: $811kMr. Stephen M. Moore J.D. (Age 52)Senior VP & Chief Legal Officer Comp: $597.98kDr. Richard Chen M.D. (Age 53)M.S., Executive VP of R&D and Chief Medical Officer Comp: $800.6kDr. Russ B. Altman M.D.Ph.D., Co-Founder and Member of Clinical & Scientific Advisory BoardDr. Euan A. Ashley DPHIL (Age 53)FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board Dr. Michael P. Snyder Ph.D.Co-Founder and Member of Clinical & Scientific Advisory BoardMr. Michael J FitzpatrickVice President of Worldwide SalesDr. Christian Haudenschild Ph.D.Senior Vice President of Genomic Laboratory OperationsMr. Stephane Mouradian Ph.D.Senior Vice President of Business DevelopmentMore ExecutivesKey CompetitorsMacroGenicsNASDAQ:MGNXViridian TherapeuticsNASDAQ:VRDNAveanna HealthcareNASDAQ:AVAHThe Pennant GroupNASDAQ:PNTGGeneDxNASDAQ:WGSView All CompetitorsInsiders & InstitutionsMarshall Wace LLPSold 101,050 shares on 8/14/2024Ownership: 0.207%XTX Topco LtdSold 100,646 shares on 8/12/2024Ownership: 0.056%Renaissance Technologies LLCSold 68,200 shares on 8/9/2024Ownership: 1.982%Dimensional Fund Advisors LPSold 10,217 shares on 8/9/2024Ownership: 0.145%Acadian Asset Management LLCBought 66,128 shares on 8/6/2024Ownership: 2.037%View All Insider TransactionsView All Institutional Transactions PSNL Stock Analysis - Frequently Asked Questions How have PSNL shares performed this year? Personalis' stock was trading at $2.10 on January 1st, 2024. Since then, PSNL shares have increased by 178.1% and is now trading at $5.84. View the best growth stocks for 2024 here. How were Personalis' earnings last quarter? Personalis, Inc. (NASDAQ:PSNL) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.10. The firm earned $22.58 million during the quarter, compared to analyst estimates of $19.81 million. Personalis had a negative net margin of 101.78% and a negative trailing twelve-month return on equity of 56.87%. What is John West's approval rating as Personalis' CEO? 17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees. When did Personalis IPO? Personalis (PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager. Who are Personalis' major shareholders? Top institutional investors of Personalis include ARK Investment Management LLC (12.25%), Acadian Asset Management LLC (2.04%), Renaissance Technologies LLC (1.98%) and Sumitomo Mitsui Trust Holdings Inc. (1.70%). Insiders that own company stock include John Stephen West, Christopher M Hall, Aaron Tachibana, Richard Chen, Stephen Michael Moore and Lightspeed Venture Partners Se. View institutional ownership trends. How do I buy shares of Personalis? Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO) and NVIDIA (NVDA). This page (NASDAQ:PSNL) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Personalis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Personalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PSNL Stock Alerts